Viewing Study NCT03658577



Ignite Creation Date: 2024-05-06 @ 12:01 PM
Last Modification Date: 2024-10-26 @ 12:53 PM
Study NCT ID: NCT03658577
Status: UNKNOWN
Last Update Posted: 2018-09-05
First Post: 2018-08-20

Brief Title: Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome
Sponsor: Shenzhen Peoples Hospital
Organization: Shenzhen Peoples Hospital

Study Overview

Official Title: Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Status: UNKNOWN
Status Verified Date: 2018-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary SyndromeACS patients This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention PCI
Detailed Description: The American College of Cardiology ACCAmerican Heart Association AHA guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy However evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis In the present era of PCI there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients Moreover results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent

In particular the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk such as preserved left ventricular systolic function or single-vessel disease Therefore we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None